Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMOUR: Aflibercept for macular oedema associated with retinitis pigmentosa
2015-003723-65Phase 2Completed
- Sponsor
- Moorfields Eye Hospital
- Start
- Jan 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aflibercept in cystoid macular edema (CME) and retinitis pigmentosa (RP), sponsored by Moorfields Eye Hospital. Primary endpoint: Mean central macular thickness at 12 months. Started Jan 2016; status: completed.
02
Drugs
aflibercept
03
Conditions
cystoid macular edema (CME)retinitis pigmentosa (RP)
Beyond the preview
Go deeper on 2015-003723-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003723-65.